Longeveron (NASDAQ:LGVN – Free Report) had its target price reduced by Maxim Group from $15.00 to $6.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock.
Separately, HC Wainwright reissued a buy rating and set a $10.00 target price on shares of Longeveron in a research note on Thursday, August 15th.
Get Our Latest Analysis on LGVN
Longeveron Stock Performance
Institutional Investors Weigh In On Longeveron
An institutional investor recently bought a new position in Longeveron stock. Renaissance Technologies LLC bought a new stake in Longeveron Inc. (NASDAQ:LGVN – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 146,700 shares of the company’s stock, valued at approximately $236,000. Renaissance Technologies LLC owned 2.31% of Longeveron as of its most recent SEC filing. 10.01% of the stock is owned by institutional investors.
Longeveron Company Profile
Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.
See Also
- Five stocks we like better than Longeveron
- How to invest in marijuana stocks in 7 stepsĀ
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- Financial Services Stocks Investing
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- Stock Market Upgrades: What Are They?
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.